Ariel Investments, an investment management company, released its "Ariel Appreciation Fund" fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund advanced +3.04% in the fourth quarter of 2025, outperforming the Russell Midcap Value Index's +1.42% and the Russell Midcap Index's +0.16% returns as U.S. equities posted a modest gain to cap a third consecutive year of double-digit returns despite earlier volatility, including a sharp spring sell-off, a prolonged government sh ...

分组1 - Invesco Small Cap Value Fund reported a quarterly return of 6.79% in Q4 2025, outperforming the Russell 2000 Value Index which returned 3.26% [1] - For the full year, the fund achieved a return of 17.64%, compared to 12.59% for the Russell 2000 Value Index [1] - The fund's performance was bolstered by stock selection in the Information Technology sector, contributing approximately 2.90% to relative performance, while health care and financials detracted [1] 分组2 - Charles River Laboratories International, Inc. (NYSE:CRL) is a leading contract research organization that supports drug discovery, development, and manufacturing for pharmaceutical and biotechnology companies [3] - The stock of Charles River Laboratories had a one-month return of -2% and traded between $91.86 and $228.88 over the last 52 weeks, closing at approximately $179.58 per share with a market capitalization of about $8.86 billion [2] - Slower spending on biotech and pharma R&D has been a headwind for Charles River Laboratories, presenting an opportunity for investment at an attractive discount to intrinsic value [3] 分组3 - At the end of Q4 2025, 53 hedge fund portfolios held shares of Charles River Laboratories, an increase from 50 in the previous quarter [5] - Despite the potential of Charles River Laboratories, there is a belief that some AI stocks may offer greater promise for higher returns in a shorter time frame [5]

Core Insights - Parsons Corporation has been awarded a $125 million contract over five years to support the U.S. Army's research and development initiatives, specifically through the Army Research Laboratory and its High Performance Computing Modernization Program [1][2] - This contract reflects Parsons' long-standing commitment to innovation and excellence in military support, continuing a partnership with the Army Research Laboratory that has lasted over 20 years [1][2] Company Overview - Parsons is recognized as a leading provider of disruptive technology in national security and global infrastructure markets, with expertise in areas such as cyber and electronic warfare, space and missile defense, and critical infrastructure protection [5] - The company emphasizes its agility and rapid development capabilities to deliver transformative solutions that enhance national security and mission readiness [2][5] Contract Details - Under the new contract, Parsons will provide a range of services including research, development, testing and evaluation, infrastructure operations, and project management [3] - The initiative aims to enhance scientific research and technology in critical areas such as information processing, network sciences, and advanced computing [2][3] Collaboration and Impact - The collaboration with the Army Research Directorate is designed to empower the Army's capabilities in AI/ML research and cybersecurity, contributing to impactful operations [2] - The contract also includes support for the Defense Research and Engineering Network operations, ensuring robust network security and effective systems administration [3]

Core Viewpoint - Jones Lang LaSalle (NYSE:JLL) is recognized as one of the top 10 real estate services stocks to buy according to hedge funds, with analysts showing positive sentiment towards the stock's potential upside [1]. Group 1: Analyst Ratings and Price Targets - Alex Kramm from UBS reaffirmed a Buy rating on JLL, raising the price target from $360 to $410, indicating a potential upside of over 22% for investors [1]. - Brendan Lynch from Barclays also increased his price target for JLL from $351 to $360 while maintaining an Equal Weight rating, reflecting Barclays' revised outlook for Real Estate Investment Trusts (REITs) [2]. Group 2: Company Overview - Jones Lang LaSalle is a global real estate services and investment management firm operating in over 80 countries, covering various property types including commercial, industrial, hotel, residential, and retail [3]. - The company provides a range of services such as purchasing, investing, development, and management of properties [3].

Group 1 - The core focus of the article is on Keysight's presentation at CES 2026, highlighting its comprehensive ecosystem for automotive design, development, validation, and cybersecurity solutions [1]

Group 1 - The core focus of the article is on Keysight's presentation at CES 2026, highlighting its comprehensive ecosystem for automotive design, development, validation, and cybersecurity solutions [1]

Financial Performance & Strategic Review - Charles River's Board supports the company's strategic direction, focusing on strengthening its scientific portfolio, divesting underperforming assets, maximizing financial performance, and maintaining disciplined capital deployment[7] - The company is refining its portfolio by selling certain underperforming or non-core businesses, representing approximately 7% of the estimated 2025 revenue[9] - These divestitures are expected to result in non-GAAP earnings per share accretion of at least $0.30 on an annualized basis once completed, excluding reinvestment benefits or interest expense impacts[9] - A new $1.0 billion stock repurchase authorization was approved by the Board in October, replacing a previous authorization under which $450.7 million in common stock had been repurchased since August 2024[10] 3Q25 Results & Updated Guidance - 3Q25 revenue was $1,004.9 million, a 0.5% decrease compared to $1,009.8 million in 3Q24, with a 1.6% organic revenue decline[13] - The GAAP EPS for 3Q25 was $1.10, a 17.3% decrease from $1.33 in 3Q24, while the non-GAAP EPS was $2.43, a 6.2% decrease from $2.59[15] - The company revised its 2025 revenue growth guidance to a decline of 1.5%-0.5% reported and a decline of 2.5%-1.5% organic[16] - The 2025 non-GAAP EPS estimate is now $10.10-$10.30, which includes a $0.10 guidance improvement at the midpoint[36] Segment Performance & Outlook - DSA (Discovery and Safety Assessment) revenue for 3Q25 was $600.7 million, a 2.3% decrease compared to $615.1 million in 3Q24, with a 3.1% organic revenue decline[17] - RMS (Research Models and Services) revenue for 3Q25 was $213.5 million, a 7.9% increase compared to $197.8 million in 3Q24, with a 6.5% organic revenue growth[25] - Manufacturing revenue for 3Q25 was $190.7 million, a 3.1% decrease compared to $196.9 million in 3Q24, with a 5.1% organic revenue decline[28]